**Social Appointments:** * Deputy Head of the Gastrointestinal Functional Disease Collaboration Group, Chinese Medical Association, Gastroenterology Branch * Vice President of the Academic Committee, Chinese Constipation Medical Association * Vice Chair of the Pancreatic Disease Professional Committee, Guangdong Health Management Association * First Executive Council Member, Guangdong Provincial Committee, Chinese Psychosomatic Gastroenterology Alliance **Published SCI Articles as Corresponding Author and First Author:** 1. A population-based epidemiologic study of irritable bowel syndrome in South China: stratified randomized study by cluster sampling. Alimentary Pharmacology & Therapeutics 2004; 19:1217-24. (-) 2. Prevalence, risk factors and impact of gastroesophageal reflux disease symptoms: A population-based study in South China. Scandinavian Journal of Gastroenterology 2005; 40:759-67. (-) 3. Stratification and symptom characteristics of non-erosive reflux disease based on acid and duodenogastroesophageal reflux. Journal of Gastroenterology and Hepatology 2008; 23:290-5. (-) 4. Prevalence and risk factors of Barrett's esophagus in patients undergoing endoscopy for upper gastrointestinal symptoms. Journal of Digestive Diseases 2010; 11:83-7. (-) 5. Cognitive-behavioral therapy for irritable bowel syndrome: A meta-analysis. Journal of Psychosomatic Research 2014; 77:1-12. (Corresponding author) 6. Control of Foxo1 Gene Expression by Co-activator P300. Journal of Biological Chemistry 2014; 289:4326-33. (-) 7. The spectra, symptom profiles and overlap of Rome III functional gastrointestinal disorders in a tertiary center in South China. Journal of Digestive Diseases 2014; 15:538-44. (-) 8. Geranylgeranylacetone protects against small-intestinal injuries induced by diclofenac in patients with rheumatic diseases: A prospective randomized study. Digestive and Liver Disease 2015; 47:280-4. (-) 9. Increased small intestinal permeability and RNA expression profiles of mucosa from terminal ileum in patients with diarrhoea-predominant irritable bowel syndrome. Digestive and Liver Disease 2016; 48:880-7. (Corresponding author) 10. Natural history of adult onset Menetrier's disease: Report of a case with 9-year follow-up. Experimental and Therapeutic Medicine 2016; 11:2462-6. (Corresponding author) 11. Rome foundation Asian working team report: Real world treatment experience of Asian patients with functional bowel disorders. Journal of Gastroenterology and Hepatology 2017; 32:1450-6. (-) 12. Prevalence of lactose intolerance in patients with diarrhea-predominant irritable bowel syndrome: data from a tertiary center in southern China. Journal of Health Population and Nutrition 2017; 36. (-) 13. Alterations of gut microbiota in patients with irritable bowel syndrome: A systematic review and meta-analysis. Journal of Gastroenterology and Hepatology 2017; 32:28-38. (Corresponding author) 14. Fecal Microbiota Alterations Associated With Diarrhea-Predominant Irritable Bowel Syndrome. Frontiers in Microbiology 2018;9. (Corresponding author) 15. Peroxisome Elevation Induces Stem Cell Differentiation and Intestinal Epithelial Repair. Developmental Cell 2020; 53: 169-184.e11. (Co-first author) 16. The propionic acid and butyric acid in serum but not in feces are increased in patients with diarrhea-predominant irritable bowel syndrome. Bmc Gastroenterology 2020; 20. (Corresponding author) 17. Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome. Bmc Gastroenterology 2020; 20. (Corresponding author) 18. Alterations in short-chain fatty acids and serotonin in irritable bowel syndrome: a systematic review and meta-analysis. Bmc Gastroenterology 2021; 21. (Corresponding author) 19. Gut Microbiota-Derived Metabolites in Irritable Bowel Syndrome. Frontiers in Cellular and Infection Microbiology 2021; 11. (Corresponding author) 20. Golden bifid might improve diarrhea-predominant irritable bowel syndrome via microbiota modulation. Journal of Health Population and Nutrition 2022; 41. (Corresponding author) 21. Gastrointestinal bleeding caused by metastatic testicular choriocarcinoma: a case report and literature review. World Journal of Surgical Oncology 2022; 20. (Corresponding author) 22. Intestinal crosstalk between bile acids and microbiota in irritable bowel syndrome. Journal of Gastroenterology and Hepatology 2023;38:1072-82. (Corresponding author) 23. Rifaximin Ameliorates Loperamide-Induced Constipation in Rats through the Regulation of Gut Microbiota and Serum Metabolites. Nutrients 2023; 15. (Corresponding author) 24. Efficacy and safety of Bifidobacterium quadruple viable tablets combined with mosapride citrate in the treatment of constipation in China: a systematic review and meta-analysis. Bmc Gastroenterology 2023; 23. (Corresponding author) 25. Outcome-Specific Efficacy of Different Probiotic Strains and Mixtures in Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis. Nutrients 2023; 15. (Corresponding author) 26. Multiomics Analysis Reveals Gut Virome-Bacteria-Metabolite Interactions and Their Associations with Symptoms in Patients with IBS-D. Viruses 2024 Jun 29;16(7):1054. (Corresponding author) 27. Diagnostic accuracy of a simplified tool for irritable bowel syndrome with predominant constipation in Chinese patients: A multicenter, prospective, observational study. Chin Med J (Eng). 2024 Oct 20; 137(20): 2509-11. (Corresponding author) 28. Bifidobacterium Lactobacillus Triple Viable Alleviates Slow Transit Constipation by Regulating Gut Microbiota and Metabolism. J Gastroenterol Hepatol. 2025 Jun; 40(6): 1561-1573. (Corresponding author) 29. Werner syndrome exonuclease promotes gut regeneration and causes age-associated gut hyperplasia in Drosophila. PLoS Biol. 2025 Apr 22;23(4):e3003121. (Co-first author) **Other Achievements:** 1) Awarded Third-Class Merit for Combating SARS and Advanced Individual in Guangzhou for Combating SARS. 2) "Series Studies on Gastroesophageal Reflux Disease" won the First Prize of the 2013 Guangzhou Science and Technology Award (Scientific and Technological Progress Category). 3) Principal Investigator for various research projects, including the National Natural Science Foundation of China, Guangdong Provincial Science and Technology Plan, Guangdong Provincial Natural Science Foundation, Sun Yat-sen University Young Teacher Fund, and Guangdong Provincial Medical Research Fund. 4) Served as a core expert and lead writer for national consensus opinions, including the 2013 "Chinese Guidelines for the Diagnosis and Treatment of Chronic Constipation," the 2015 "Chinese Expert Consensus on Irritable Bowel Syndrome," the "2019 Chinese Consensus on Chronic Constipation," the "2020 Chinese Expert Consensus on Irritable Bowel Syndrome," the 2024 "Expert Consensus on the Clinical Application of Bifidobacterium Quadruple Viable Tablets in Digestive Diseases," the 2024 "Chinese Expert Recommendations for Rational Use of Drugs for Dyspepsia in the Family Setting (Popular Science Practice Edition)," and the "Expert Consensus on the Diagnosis and Treatment of Functional Constipation with Integrated Traditional Chinese and Western Medicine (2025)."